Unknown

Dataset Information

0

Structural Re-engineering of the ?-Helix Mimetic JY-1-106 into Small Molecules: Disruption of the Mcl-1-Bak-BH3 Protein-Protein Interaction with 2,6-Di-Substituted Nicotinates.


ABSTRACT: The disruption of aberrant protein-protein interactions (PPIs) with synthetic agents remains a challenging goal in contemporary medicinal chemistry but some progress has been made. One such dysregulated PPI is that between the anti-apoptotic Bcl-2 proteins, including myeloid cell leukemia-1 (Mcl-1), and the ?-helical Bcl-2 homology-3 (BH3) domains of its pro-apoptotic counterparts, such as Bak. Herein, we describe the discovery of small-molecule inhibitors of the Mcl-1 oncoprotein based on a novel chemotype. Particularly, re-engineering of our ?-helix mimetic JY-1-106 into 2,6-di-substituted nicotinates afforded inhibitors of comparable potencies but with significantly decreased molecular weights. The most potent inhibitor 2-(benzyloxy)-6-(4-chloro-3,5-dimethylphenoxy)nicotinic acid (1?r: Ki =2.90??m) likely binds in the p2 pocket of Mcl-1 and engages R263 in a salt bridge through its carboxylic acid, as supported by 2D (1) H-(15) N HSQC?NMR data. Significantly, inhibitors were easily accessed in just four steps, which will facilitate future optimization efforts.

SUBMITTER: Drennen B 

PROVIDER: S-EPMC4838500 | biostudies-literature | 2016 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Structural Re-engineering of the α-Helix Mimetic JY-1-106 into Small Molecules: Disruption of the Mcl-1-Bak-BH3 Protein-Protein Interaction with 2,6-Di-Substituted Nicotinates.

Drennen Brandon B   Scheenstra Jacob A JA   Yap Jeremy L JL   Chen Lijia L   Lanning Maryanna E ME   Roth Braden M BM   Wilder Paul T PT   Fletcher Steven S  

ChemMedChem 20160204 8


The disruption of aberrant protein-protein interactions (PPIs) with synthetic agents remains a challenging goal in contemporary medicinal chemistry but some progress has been made. One such dysregulated PPI is that between the anti-apoptotic Bcl-2 proteins, including myeloid cell leukemia-1 (Mcl-1), and the α-helical Bcl-2 homology-3 (BH3) domains of its pro-apoptotic counterparts, such as Bak. Herein, we describe the discovery of small-molecule inhibitors of the Mcl-1 oncoprotein based on a nov  ...[more]

Similar Datasets

| S-EPMC3663763 | biostudies-literature
| S-EPMC2953559 | biostudies-literature
| S-EPMC3033224 | biostudies-literature
| S-EPMC6888900 | biostudies-literature
| S-EPMC5864222 | biostudies-literature
| S-EPMC3135403 | biostudies-literature
| S-EPMC4937737 | biostudies-literature
| S-EPMC3040859 | biostudies-literature
| S-EPMC3059047 | biostudies-literature
| S-EPMC2948486 | biostudies-literature